6HN Stoklara Genel Bakış Bir biyofarmasötik şirketi olan Everest Medicines Limited, Büyük Çin ve diğer Asya Pasifik pazarlarında karşılanmamış kritik tıbbi ihtiyaçları karşılamak için tedavilerin ve aşıların keşfi, lisanslanması, geliştirilmesi ve ticarileştirilmesi ile ilgilenmektedir. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Everest Medicines Limited Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Everest Medicines Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı HK$4.84 52 Haftanın En Yüksek Seviyesi HK$6.00 52 Haftanın En Düşük Seviyesi HK$1.65 Beta 1.82 1 Aylık Değişim -12.00% 3 Aylık Değişim 41.52% 1 Yıllık Değişim 144.44% 3 Yıllık Değişim 45.78% 5 Yıllık Değişim n/a Halka arzdan bu yana değişim -53.01%
Son Haberler & Güncellemeler
Everest Medicines Announces First Prescription of VELSIPITY in Greater Bay Area, Officially Benefiting Mainland China Patients Dec 18
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY by the National Medical Products Administration of China for the Treatment of Moderately to Severely Active Ulcerative Colitis Dec 17
Everest Medicines Announces the First Prescription of VELSIPITY® Issued in Macau, Officially Beginning to Benefit Asian Patients Dec 12
Everest Medicines Announces Acceptance of Velsipity New Drug Application in Hong Kong Dec 02
Everest Medicines Announces Nefecon, the World's First Approved Treatment for IGA Nephropathy, Is Included in China's National Reimbursement Drug List Nov 28
Everest Medicines Announces Two In Vitro Studies on Eravacycline (XERAVA) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity Nov 22 Daha fazla güncelleme görün
Everest Medicines Announces First Prescription of VELSIPITY in Greater Bay Area, Officially Benefiting Mainland China Patients Dec 18
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY by the National Medical Products Administration of China for the Treatment of Moderately to Severely Active Ulcerative Colitis Dec 17
Everest Medicines Announces the First Prescription of VELSIPITY® Issued in Macau, Officially Beginning to Benefit Asian Patients Dec 12
Everest Medicines Announces Acceptance of Velsipity New Drug Application in Hong Kong Dec 02
Everest Medicines Announces Nefecon, the World's First Approved Treatment for IGA Nephropathy, Is Included in China's National Reimbursement Drug List Nov 28
Everest Medicines Announces Two In Vitro Studies on Eravacycline (XERAVA) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity Nov 22
Everest Medicines Announces NEFECON Receives Full Approval from South Korea's Ministry of Food and Drug Safety for the Treatment of Primary IgA Nephropathy Nov 19
Everest Medicines Limited Announces Business Update on NEFECON Development Oct 24
Now 21% undervalued Oct 03
First half 2024 earnings released Sep 02
No longer forecast to breakeven Aug 28
New minor risk - Profitability Aug 28
Everest Medicines Limited to Report First Half, 2024 Results on Aug 27, 2024 Aug 05
Everest Medicines Announces First Chinese Patient Dosed in Global Phase 2b PALIZADE Trial of Zetomipzomib in Lupus Nephritis Jul 22
Now 21% undervalued after recent price drop Jul 19
Everest Medicines Announces Official Acceptance Granted on NEFECON® Supplementary Application by China National Medical Products Administration Jul 18
Everest Medicines Announces Positive Topline Results from Maintenance Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderately-to-Severely Active Ulcerative Colitis Jul 15
Everest Medicines Limited, Annual General Meeting, Jun 28, 2024 Jun 06
Everest Medicines Announces Commercial Launch and First Prescription for NEFECON in Mainland China May 15
Now 22% overvalued after recent price rise May 10
Everest Medicines Announces New Drug Application Approval of Velsipity® for Adults with Moderately to Severely Active Ulcerative Colitis in Macau May 08
Everest Medicines Announces Hong Kong Department of Health Approval of Nefecon® for the Treatment for Primary IgA Nephropathy in Adult Patients May 02
Full year 2023 earnings released Mar 30
Forecast to breakeven in 2026 Mar 28
Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer Mar 19
Now 23% overvalued after recent price rise Mar 18
Everest Medicines Limited to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 06
Everest Medicines Limited Announces Board Changes Feb 09
Now 22% undervalued after recent price drop Jan 30
Everest Medicines Limited Provides Earning Guidance for the Year Ended 31 December 2023 Jan 22
Everest Medicines Limited Announces Directorate Changes Jan 12
Everest Medicines Announces New Drug Application Acceptance of Nefecon® in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patients Dec 27 Everest Medicines Reaffirms Revenue Guidance for the Year 2023 and 2024 Nov 29
Calliditas’ Partner Everest Medicines Announces China NMPA’s Approval of Nefecon® for the Treatment of Primary IgA Nephropathy Nov 27
National Medical Products Administration Approves the New Drug Application for Nefecon for the Treatment of Primary Immunoglobulin A Nephropathy in Adults At Risk of Disease Progress in China Nov 25
Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy Oct 27
Everest Medicines Limited Announces Approval of XERAVA® in Taiwan for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients Sep 28
New major risk - Revenue and earnings growth Aug 28
First half 2023 earnings released: CN¥1.40 loss per share (vs CN¥2.26 loss in 1H 2022) Aug 27
Everest Medicines Announces New Drug Application Acceptance by the Pharmaceutical Administration Bureau of Macao for Nefecon(R) for the Treatment of Primary IgA Nephropathy Aug 25
Everest Medicines Limited to Report First Half, 2023 Results on Aug 24, 2023 Aug 09
Everest Medicines Announces Completion of Patient Enrollment in Nefecon®? China Open Label Extension Study Aug 02
Everest Medicines Announces Commercial Launch and First Prescription for XERAVA in China Jul 27
Everest Medicines Appoints Mike Berry as Chief Technology Officer Jun 16
Everest Medicines Limited, Annual General Meeting, Jun 29, 2023 May 31
Everest Medicines Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Etrasimod in Asia May 17
No longer forecast to breakeven Apr 03
Everest Medicines Announces South Korea Grants Fast Track Review Designation to Nefecon for the Treatment of Primary Iga Nephropathy Feb 10
Everest Medicines Limited Announces Board Changes Jan 20 Everest Medicines Announces Top-line Data from Phase I Study of EVER206 on Healthy Subjects in China Jan 18
Everest Medicines Aims to Initiate Clinical Trials and File an Emergency Use Authorization Application in 2023 in China for Its Lead mRNA Candidate Jan 04 Everest Medicines Announces China NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy
Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone Dec 15
Everest Medicines Announces Major Regulatory Updates in Taiwan and South Korea for Nefecon for the Treatment of Primary IgA Nephropathy Nov 28
Less than half of directors are independent Nov 16
Everest Medicines Announces New Drug Application Acceptance by China NMPA for Nefecon for the Treatment of Primary IgA Nephropathy Nov 15
Everest Medicines Announces Approval of XERAVA in Hong Kong for the Treatment of Complicated Intra-Abdominal Infections Oct 08
Forecast to breakeven in 2022 Sep 27
Everest Medicines Receives Approval of Investigational New Drug Application from China NMPA for EVER001 Sep 26 Everest Medicines Appoints Rogers Yongqing Luo as an Executive Director Everest Medicines Limited Announces Resignation of Kerry Blanchard as A Member of the Board of Directors
Everest Medicines Limited to Report First Half, 2022 Results on Aug 24, 2022 Aug 13
Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava™ in Taiwan Aug 11
Everest Medicines Announces Approval of Trodelvy in China for Second-Line Metastatic Triple-Negative Breast Cancer Jun 10
Less than half of directors are independent Apr 27
Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent With Global Phase 3 NefIgArd Study Part A Analysis Apr 06 Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan
Forecast to breakeven in 2024 Mar 30
Everest Medicines Limited, Annual General Meeting, Jun 30, 2022 Mar 30
Everest Medicines Limited Appoints Leah Liu as Joint Company Secretary Mar 29
Everest Medicines Announces First Drug Approval of Trodelvy® in Singapore for Second-Line Metastatic Triple-Negative Breast Cancer Feb 07
Everest Medicines Limited Announces Resignation of Ms. Yin Yin as Joint Company Secretary Feb 01
Everest Medicines Will Participate in Clinical Trial with Gilead and Msd to Evaluate Trodelvy® in Combination with Keytruda® (Pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer Jan 12
Everest Medicines Limited Announces Taiwan FDA Has Accepts New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer Jan 04
Everest Medicines and Providence Therapeutics announces that PTX-COVID19-B, a mRNA Vaccine for COVID-19, has received approval for inclusion in WHO Solidarity Trial Vaccines (STV) Program Dec 21
Everest Medicines Limited Announces Acceptance of New Drug Application for Sacituzumab Govitecan Dec 15
Everest Medicines Limited Receives Approval for Investigational New Drug Application for SPR206 from National Medical Products Administration Sep 25
Everest Medicines Announces First Person Dosed in Global Phase 3 Registration Trial of Sacituzumab Govitecan-Hziy in China for Metastatic Urothelial Cancer Aug 27
Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Phase 3 Trial of Xerava(TM) for Community-Acquired Bacterial Pneumonia Aug 06
Everest Medicines Announces China NMPA Has Granted Priority Review for Sacituzumab Govitecan-hziy in Metastatic Triple-Negative Breast Cancer May 21
Everest Medicines announces that the China National Medical Products Administration has accepted for review its Biologics License Application for sacituzumab govitecan-hziy May 18
Everest Medicines Limited Receives Orphan Drug Designation from the Ministry of Food and Drug Safety in South Korea for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer May 07
Everest Medicines Limited to Report Fiscal Year 2020 Results on Mar 21, 2021 Mar 11 Hissedar Getirileri 6HN DE Biotechs DE Pazar 7D 0.8% -2.1% 3.0% 1Y 144.4% -3.8% 12.8%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: 6HN geçen yıl % -3.8 oranında getiri sağlayan German Biotechs sektörünü aştı.
Getiri vs Piyasa: 6HN geçen yıl % 12.8 oranında getiri sağlayan German Piyasasını aştı.
Fiyat Oynaklığı Is 6HN's price volatile compared to industry and market? 6HN volatility 6HN Average Weekly Movement 12.6% Biotechs Industry Average Movement 6.2% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
İstikrarlı Hisse Senedi Fiyatı: 6HN hisse senedi fiyatı, son 3 ayda German piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: 6HN 'nin haftalık oynaklığı ( 13% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.
Şirket Hakkında Bir biyofarmasötik şirketi olan Everest Medicines Limited, Büyük Çin ve diğer Asya Pasifik pazarlarında karşılanmamış kritik tıbbi ihtiyaçları karşılamak için tedavilerin ve aşıların keşfi, lisanslanması, geliştirilmesi ve ticarileştirilmesi ile ilgilenmektedir. Boru hattı, immünoglobulin nefropatisinin (IgAN) tedavisi için budesonidin oral bir formülasyonu olan Nefecon'u; duyarlı gram-pozitif, gram-negatif ve anaerobik patojenlerin neden olduğu enfeksiyonların tedavisi için tamamen sentetik bir florosiklin intravenöz antibiyotik olan Xerava'yı içerir; Ciddi bakteriyel enfeksiyonları olan hastaların tedavisi için faz 3 klinik çalışmada olan bir beta-laktamaz inhibitörü (BLI) olan Taniborbactam; ve orta ila şiddetli aktif ülseratif kolit tedavisi için faz 3 klinik çalışmada olan bir oral selektif sfingozin 1-fosfat (S1P) reseptör modülatörü olan Etrasimod. Şirket, lupus nefriti de dahil olmak üzere bir dizi bağışıklık aracılı hastalık için faz 2b klinik çalışmasında olan bir immünoproteazom inhibitörü olan Zetomipzomib; böbrek hastalıklarının tedavisi için faz 1b klinik çalışmasında olan kovalent geri dönüşümlü bir Bruton tirozin kinaz (BTK) inhibitörü olan EVER001; ve kanser ve otoimmün hastalıklar için mRNA platformu terapötik aşıları sunmaktadır.
Daha fazla göster Everest Medicines Limited Temel Bilgiler Özeti Everest Medicines'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? 6HN temel i̇stati̇sti̇kler Piyasa değeri €1.56b Kazançlar(TTM ) -€139.91m Gelir(TTM ) €55.60m
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) 6HN gelir tablosu (TTM ) Gelir CN¥418.55m Gelir Maliyeti CN¥101.53m Brüt Kâr CN¥317.02m Diğer Giderler CN¥1.37b Kazançlar -CN¥1.05b
Son Raporlanan Kazançlar
Jun 30, 2024
Hisse başına kazanç (EPS) -3.27 Brüt Marj 75.74% Net Kâr Marjı -251.64% Borç/Özkaynak Oranı 10.9%
6HN uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görün
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2025/01/20 09:23 Gün Sonu Hisse Fiyatı 2025/01/17 00:00 Kazançlar 2024/06/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları Everest Medicines Limited 13 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Bo Li BofA Global Research Ziyu He China International Capital Corporation Limited Jin Zhang China International Capital Corporation Limited
Göster 10 daha fazla analist 
